MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-26-0655

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG.

Lindsay Holly B, Billups Catherine A, Kocak Mehmet, Alban Tyler J, Young Poussaint Tina, Wong Phillip, Chan Timothy A, Kovacic Benjamin, Makarov Vladimir, Juric Ivan, Diaz-Montero C Marcela, Srivastava Raghvendra, Pavicic Paul, Parthasarathy Prerana, Lenzen Alicia, MacDonald Tobey J, Pollack Ian F, Vinitsky Anna, Robison Nathan J, Baxter Patricia, Hwang Eugene I, Leggas Markos, Khalil Danny N, Fangusaro Jason, Onar-Thomas Arzu, Dunkel Ira J

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: The PBTC-051 study is the first pediatric evaluation of a CD40 agonist and assessed the safety, pharmacokinetics, and preliminary efficacy of sotigalimab in children and young adults with recurrent or progressive malignant central nervous system (CNS) tumors (stratum 1) and postradiation preprogression diffuse intrinsic pontine glioma (DIPG; stratum 2).

PATIENTS AND

METHODS

This prospective phase I study conducted by the Pediatric Brain Tumor Consortium evaluated sotigalimab using a 3 + 3 design for dose escalation. Immune pharmacodynamics was assessed with RNA transcript analysis, T-cell receptor sequencing, and cytokine profiling.

RESULTS

Thirty-one eligible patients were enrolled (stratum 1: 20, stratum 2: 11). The stratum 1 recommended phase II dose was 0.6 mg/kg every 3 weeks; the stratum 2 maximum tolerated dose was 0.3 mg/kg every 3 weeks. Five patients had dose-limiting toxicities. No patients had an objective response. For stratum 1, 6- and 12-month progression-free survivals (PFS) were 13.3% [standard error (SE), 8.1%] and 6.7% (SE, 6.2%), respectively; for stratum 2, 6-month PFS and overall survival were 31.2% (SE, 14.8%) and 44.4% (SE, 16.6%), respectively. At all dose levels, the maximum serum concentration was reached at the end of infusion; no drug accumulation was detected. More than 40% of patients developed antidrug antibodies. Signaling pathways associated with activated antigen-presenting cells and T cells were enriched in patients with higher PFS, whereas increased loss of heterozygosity was noted in patients with lower PFS.

CONCLUSIONS

Sotigalimab was well-tolerated in pediatric patients with recurrent or progressive CNS tumors and postradiation preprogression DIPG.

Для цитирования: Lindsay Holly B, Billups Catherine A, Kocak Mehmet, Alban Tyler J, Young Poussaint Tina, Wong Phillip, Chan Timothy A, Kovacic Benjamin, Makarov Vladimir, Juric Ivan, Diaz-Montero C Marcela, Srivastava Raghvendra, Pavicic Paul, Parthasarathy Prerana, Lenzen Alicia, MacDonald Tobey J, Pollack Ian F, Vinitsky Anna, Robison Nathan J, Baxter Patricia, Hwang Eugene I, Leggas Markos, Khalil Danny N, Fangusaro Jason, Onar-Thomas Arzu, Dunkel Ira J. Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. DOI: 10.1158/1078-0432.ccr-26-0655.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.